ERBB2 and breast carcinoma: There were no significant differences in the frequency of events determining iDFS in patients stratified by molecular subtype of breast cancer who underwent upfront surgery (luminal: 2.54%; TNBC: 1.69%; HER2+: 3.95%) (Figure 4B; Supplementary Table S4).